Vitruvian Partners LLP Maxcyte, Inc. Transaction History
Vitruvian Partners LLP
- $116 Million
- Q4 2024
A detailed history of Vitruvian Partners LLP transactions in Maxcyte, Inc. stock. As of the latest transaction made, Vitruvian Partners LLP holds 5,043,356 shares of MXCT stock, worth $19.4 Million. This represents 18.06% of its overall portfolio holdings.
Number of Shares
5,043,356
Previous 5,043,356
-0.0%
Holding current value
$19.4 Million
Previous $19.6 Million
6.94%
% of portfolio
18.06%
Previous 7.62%
Shares
3 transactions
Others Institutions Holding MXCT
# of Institutions
123Shares Held
69.8MCall Options Held
8.7KPut Options Held
6K-
Cadian Capital Management, LP New York, NY9.34MShares$36 Million2.26% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$31.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.43MShares$20.9 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.41MShares$17 Million0.0% of portfolio
-
Mirabella Financial Services LLP London, X03.7MShares$14.2 Million1.48% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $392M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...